BIT 4.76% 2.0¢ biotron limited

Ann: Biotron to Test its Compounds Against Coronavirus, page-701

ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
  1. 16,487 Posts.
    lightbulb Created with Sketch. 777
    Its looking less likely existing Biotron compounds or new compounds found will play a role in a treatment imo. No one but Biotron is seeing the E protein as a target.


    https://www.nature.com/articles/s41586-020-2223-y

    Abstract

    A new coronavirus (CoV) identified as COVID-19 virus is the etiological agent responsible for the 2019-2020 viral pneumonia outbreak that commenced in Wuhan1–4. Currently there are no targeted therapeutics and effective treatment options remain very limited. In order to rapidly discover lead compounds for clinical use, we initiated a program of combined structure-assisted drug design, virtual drug screening and high-throughput screening to identify new drug leads that target the COVID-19 virus main protease (Mpro). Mpro is a key CoV enzyme, which plays a pivotal role in mediating viral replication and transcription, making it an attractive drug target for this virus5,6. Here, we identified a mechanism-based inhibitor, N3, by computer-aided drug design and subsequently determined the crystal structure of COVID-19 virus Mpro in complex with this compound. Next, through a combination of structure-based virtual and high-throughput screening, we assayed over 10,000 compounds including approved drugs, drug candidates in clinical trials, and other pharmacologically active compounds as inhibitors of Mpro. Six of these compounds inhibited Mpro with IC50 values ranging from 0.67 to 21.4 μM. Ebselen also exhibited promising antiviral activity in cell-based assays. Our results demonstrate the efficacy of this screening strategy, which can lead to the rapid discovery of drug leads with clinical potential in response to new infectious diseases for which no specific drugs or vaccines are available

 
watchlist Created with Sketch. Add BIT (ASX) to my watchlist
(20min delay)
Last
2.0¢
Change
-0.001(4.76%)
Mkt cap ! $18.04M
Open High Low Value Volume
2.1¢ 2.1¢ 2.0¢ $12.00K 600.2K

Buyers (Bids)

No. Vol. Price($)
5 972631 1.9¢
 

Sellers (Offers)

Price($) Vol. No.
2.1¢ 199783 1
View Market Depth
Last trade - 14.33pm 01/11/2024 (20 minute delay) ?
BIT (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.